What is Pulike Biological Engineering, Inc.'s (603566.SS) StockRank?

MoatMap's StockRank for Pulike Biological Engineering, Inc. (603566.SS) is 74/100, with a Buy signal. This is a composite score combining Quality (66), Value (52), and Momentum (43) factor ranks across MoatMap's 19,000+ stock universe.

Does Pulike Biological Engineering, Inc. have an economic moat?

Pulike Biological Engineering, Inc. (603566.SS) has a Quality factor score of 66/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Pulike Biological Engineering, Inc. a buy, hold, or sell?

MoatMap's current signal for Pulike Biological Engineering, Inc. (603566.SS) is Buy, based on a StockRank of 74/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Pulike Biological Engineering, Inc. in?

Pulike Biological Engineering, Inc. (603566.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

603566.SS

BUYREMOVE

Pulike Biological Engineering, Inc. · Healthcare · China · $543M · Avg Vol: $5M/d

StockRank

P/E (TTM)

21.1x

ROE

6.2%

D/E

0.0x

Dividend %

5.7%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Pulike Biological Engineering develops animal vaccines. While it has decent quality metrics, it is highly dependent on agricultural cycles and domestic livestock disease outbreaks, with no connection to our core macro themes.

COMPANY DESCRIPTION

Pulike Biological Engineering is a leading high-tech enterprise specializing in the research, development, and manufacturing of veterinary vaccines and animal health products. The company possesses a strong competitive moat driven by its state-of-the-art R&D platforms, including a National Engineering Research Center, and its pioneering work in genetic engineering vaccines for swine and poultry. It is a dominant player in China's animal health sector, benefiting from the modernization and consolidation of the livestock industry.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	182M	185M	154M	161M	-4.0%
EPS	0.08	0.07	0.04	0.08	1.3%
Shares	353M	353M	346M	346M	-1.9%
Debt	1M	303,331	185,727	4M	41.1%
Equity	414M	403M	388M	385M	-2.4%
Op CF	34M	42M	40M	53M	16.0%
Inv CF	-141M	-245,650	-28M	-32M	—
Fin CF	123M	-36M	-28M	-31M	—

PRICE (1M)-11.9%

SMA 50SMA 200

$1.56

RSI (14)

44.2

52W High

$2.30

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

7.4%64.8

ROE

6.2%59.4

GP/Assets

19.3%45.2

Op. Margin

15.6%75.8

FCF/Assets

1.7%56.7

Piotroski

—83.5

Int. Cover

50.0x91.4

D/E Ratio

0.01x88.4

Current Ratio

3.82x62.2

Value

P/E (TTM)

21.1x54.7

EV/EBITDA

10.8x39.8

P/FCF

445.7x16.9

P/B

1.4x69.8

P/S

3.4x52.3

Div Yield

5.7%94.8

Momentum

52W High %

68%53.0

RS 6M

-28%44.1

SMA 50/200

0.88x28.4

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+64%60.3

Q Growth

-23%22.0

FUNDAMENTALS

Market Cap

$543M

P/E (Forward)

12.9x

Gross Margin

58.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 603566.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
603566.SS	Pulike Biological Engineering, Inc.(you)	$543M	74	BUY
2509.HK	Qyuns Therapeutics Co., Ltd.	$483M	74	BUY
6826.HK	Shanghai Haohai Biological Technology Co., Ltd.	$523M	82	STRONG BUY
1875.HK	BioDlink International Company Limited	$383M	68	BUY
300841.SZ	Chengdu Kanghua Biological Products Co., Ltd.	$917M	67	BUY
301047.SZ	Sino Biological,Inc.	$1.1B	70	BUY
688526.SS	Wuhan Keqian Biology Co.,Ltd	$906M	83	STRONG BUY
688046.SS	GemPharmatech Co., Ltd.	$1.2B	70	BUY
3880.HK	Medtide Inc.	$393M	89	STRONG BUY
688315.SS	Novogene Co., Ltd.	$870M	60	HOLD

Peer medians: ROE 4.7% · P/E 27.9x · Gross margin 53.0%

Pulike Biological Engineering, Inc. (603566.SS) — Stock Score Summary

Pulike Biological Engineering, Inc. (603566.SS) has a MoatMap StockRank of 74/100 based on Quality (66/100), Value (52/100), and Momentum (43/100) factor scores. The current signal is BUY. Pulike Biological Engineering develops animal vaccines. While it has decent quality metrics, it is highly dependent on agricultural cycles and domestic livestock disease outbreaks, with no connection to our core macro themes.

Key Financial Metrics

Price	$1.56
Market Cap	$543M
P/E (TTM)	21.10
P/E (Forward)	12.87
Price/Book	1.36
Return on Equity	6.2%
Return on Invested Capital	7.4%
Debt/Equity	0.98
Gross Margin	58.7%
Operating Margin	15.6%
Revenue Growth	-10.5%
Dividend Yield	5.7%
Free Cash Flow	$1M

Pulike Biological Engineering, Inc. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Pulike Biological Engineering, Inc.’s (603566.SS) StockRank?: MoatMap’s StockRank for Pulike Biological Engineering, Inc. (603566.SS) is 74/100, with a Buy signal. It is a composite of Quality (66), Value (52), and Momentum (43) factor ranks across MoatMap’s 19,000+ stock universe.
Does Pulike Biological Engineering, Inc. have an economic moat?: Pulike Biological Engineering, Inc. (603566.SS) has a Quality factor score of 66/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Pulike Biological Engineering, Inc. a buy, hold, or sell?: MoatMap’s current signal for Pulike Biological Engineering, Inc. (603566.SS) is Buy, based on a StockRank of 74/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Pulike Biological Engineering, Inc. in?: Pulike Biological Engineering, Inc. (603566.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).